Announcement on the 2018 Profit Distribution Plan
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviations: Jianfeng Group No.: Pro 2019-015
Bond Abbreviations: 13 Peak 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on 2018 Profit Distribution Plan
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Content Note:
l
Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company") 2018 Profit Distribution Plan is based on 2018 year-end share capital ,344,083, 828 shares, cash dividends 3.0 yuan (tax included) are distributed for every 10 shares, and the total cash dividends to all shareholders registered on the equity registration date are 103,225,148.40 yuan (tax included).
l
Review Procedure: This profit distribution plan has been reviewed and approved at the 10th meeting of the 10th Board of Directors of the Company, and still needs to be submitted to the 2018 Annual General Meeting of Shareholders of the Company for review.
1. 2018 The main contents of the profit distribution plan
are audited by Tianjian Certified Public Accountants (Special General Partnership). The net profit attributable to the shareholders of the parent company in the consolidated statement of 2018 is ,588,502,101.59 yuan. Net profit in accounting statement of parent company ,433,675,496.73 yuan. According to the parent company's current net profit as the base, extract 10% statutory provident fund 43,367,549.67 yuan, plus undistributed profit 658,978,622.43 yuan at the beginning of the year, minus 2017 annual cash dividend 34,408,382.80 yuan, and the distributable profit for this year is 1,014,878,186.69 yuan.
Company plans to make cash distribution in 2018 . Based on 2018 year-end share capital ,344,083, 828 shares, it will distribute cash dividends 3.0 yuan (including tax) per 10 shares, and the total amount of cash dividends to all shareholders registered on the equity registration date will be , 225,148.40 yuan (tax included).
2018 year will not carry out provident fund to increase share capital.
2. Profit Distribution Plan Description
( 1 ) Implementation of the Company's Cash Dividend Policy
The Articles of Association of the Company stipulate that the accumulated profits distributed in cash in the last three years shall not be less than the 30% of the average annual distributable profits realized in the last three years.
The proportion of the company's accumulated profits distributed in cash in the last three years to the average annual distributable profits realized in the last three years is 89.59 , which is in line with the cash dividend policy stipulated in the company's "Articles of Association.
( 2 ) Company's Development
At present, the company is in the stage of accelerated development. The company will speed up the project of Guizhou Huangpinggu Longmingchuan Cement Co., Ltd. On the basis of acquiring the 100% equity of the company, the company will continue to invest about 6.5 .3 billion yuan to build a new dry cement production line with a daily output of of 4500 tons of cement clinker (with waste heat for power generation); the total investment for the project of producing 20 .7 billion solid preparations in Jinxi production base of Jianfeng pharmaceutical industry with an annual output of is expected to be 50146 .49 million yuan, and 2019 will carry out plant construction and equipment procurement. Anhui Zhongwang, a subsidiary of Shanghai Beika, a subsidiary of Jianfeng Pharmaceutical Company, will carry out the second phase of technological transformation to build an intermediate and bulk drug base for the company's pharmaceutical sector. In addition, spike Pharmaceuticals has a number of new drugs in various stages of research and development, anti-tumor new drug "DPT " has entered the clinical stage, Spike Pharmaceuticals and its subsidiaries Zhejiang Erying, Spike Yien will further increase product research and development and introduction efforts, the need to increase investment in research and development. The development of the above-mentioned business requires large financial support.
( 3 ) Considering that the company has invested a lot in technological transformation and new product development in 2018 , in order to maintain the company's stable operation and support the company's long-term development, Taking into account the short-term and long-term interests of shareholders, the board of directors approved the above-mentioned 2018 profit distribution plan.
( 4 ) The company will hold a 2018 annual performance and cash dividend explanation meeting to communicate and exchange with investors on the company's 2018 annual performance and cash dividend matters, and timely answer investors' concerns.
3. Review Procedure
2019 4 26 , the company held the 184 meeting of the 10th 183 of the 10th Board of Directors. The company currently has nine directors, eight of whom attended the meeting in person. Director Du Zihong entrusted Director Jiang Xiaomeng to attend the meeting and vote on his behalf, comply with the relevant provisions of the "Company Law" and the "Articles of Association" of the company, and the resolutions made are legal and valid. The meeting was presided over by Chairman Jiang Xiaomeng. After deliberation and voting, the company's 2018 profit distribution plan was deliberated and approved with 9 votes in favor, 0 votes against, and 0 abstentions.
2018 Annual General Meeting of Shareholders for deliberation. When the company convenes the general meeting of shareholders, it will provide investors with online voting facilities.
2018 :
, and the independent director agreed that the company should use 2018 year-end share capital ,344,083, 828 as the base, A cash dividend of 3.0 yuan (tax included) will be distributed to 10 shares of , and the total amount of cash dividends distributed to all shareholders registered on the date of equity registration is ,148.40 yuan (tax included), No provident fund will be converted into share capital in 2018 .
. The profit distribution plan is formulated according to the actual operating results and financial situation of the company 2018 , and in combination with the actual needs of the company's future business development. The retained undistributed profits are mainly used to meet the capital needs of the company's development, which is conducive to the sustainable and healthy development of the company and the long-term interests of shareholders, and there is no harm to the rights and interests of shareholders, especially small and medium shareholders. The independent directors believe that the plan complies with the relevant provisions of the Company's Articles of Association on profit distribution and the actual operating conditions of the Company.
3 , the company's board of directors considered and approved the above profit distribution plan. The independent directors believe that the convening, convening, and deliberation and voting procedures of this meeting are in compliance with relevant laws, regulations and the "Articles of Association", and are legal and effective; and agree to submit the plan to the company's 2018 Annual General Meeting for deliberation.
5. Related Risk Tips
This profit distribution plan must be submitted to the company's 2018 annual general meeting for deliberation and approval before implementation. Investors are kindly requested to pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
April 30, 2019
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31